Gemphire Therapeutics Inc (GEMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Gemphire Therapeutics Inc (GEMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH423494D
  • |
  • Pages: 72
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Gemphire Therapeutics Inc (Gemphire), formerly Michigan Life Therapeutics LLC, is a clinical stage biopharmaceutical company that develops and commercializes therapies for patients with cardiometabolic disorders, including dyslipidemia and non-alcoholic steatohepatitis (NASH). Its lead product, Gemcabene (CI-1027), which is licensed from Pfizer is an oral therapy that targets known lipid metabolic pathways, lowering levels of LDL-C, inflammation and triglycerides. The company is evaluating gemcabene in clinical trials to enhance the clearance of very low-density lipoproteins (VLDLs) and to and inhibit the production of fatty acids and cholesterol in the liver. Gemphire is headquartered in Livonia, Michigan, the US.

Gemphire Therapeutics Inc (GEMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Gemphire Therapeutics Raises USD5 Million in Financing Round 11

Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12

Merger 13

Michigan Life Therapeutics Merges with Gemphire Therapeutics 13

Equity Offering 14

Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14

Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16

Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17

Gemphire Therapeutics Raises USD30 Million in IPO 18

Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20

Debt Offering 21

Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21

Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22

Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23

Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24

Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25

Gemphire Therapeutics Inc-Key Competitors 26

Gemphire Therapeutics Inc-Key Employees 27

Gemphire Therapeutics Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Aug 13, 2018: Gemphire Therapeutics reports second quarter 2018 financial results and provides corporate update 29

May 08, 2018: Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 31

Mar 15, 2018: Gemphire Therapeutics Announces Fourth Quarter And Fiscal Year 2017 Financial Results 33

Nov 13, 2017: Gemphire Therapeutics Reports Third Quarter 2017 Financial Results 35

Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 09, 2017: Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 15, 2017: Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update 41

Corporate Communications 44

May 03, 2018: Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer 44

May 30, 2017: Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch 45

Mar 29, 2017: Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 46

Product News 47

02/27/2018: Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease and NASH to be Rescheduled 47

02/21/2018: Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease and NASH 48

Clinical Trials 50

Jan 31, 2018: Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease 50

Jan 17, 2018: Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia Patients 52

Dec 21, 2017: Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program 53

Nov 13, 2017: Gemphire Therapeutics Presents Data at American Heart Association Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population 55

Oct 23, 2017: Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting 2017 56

Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit 57

Sep 19, 2017: Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development 59

Sep 14, 2017: Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene 62

Aug 07, 2017: Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients 63

Jun 28, 2017: Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients 64

May 01, 2017: Gemphire to Present at ATVB|PVD 2017 Scientific Sessions 66

Mar 21, 2017: Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization 67

Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial 68

Jan 09, 2017: Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study 70

Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72

List of Figures

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Gemphire Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Gemphire Therapeutics Raises USD5 Million in Financing Round 11

Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12

Michigan Life Therapeutics Merges with Gemphire Therapeutics 13

Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14

Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16

Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17

Gemphire Therapeutics Raises USD30 Million in IPO 18

Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20

Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21

Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22

Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23

Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24

Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25

Gemphire Therapeutics Inc, Key Competitors 26

Gemphire Therapeutics Inc, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Gemphire Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17855
Site License
USD 500 INR 35710
Corporate User License
USD 750 INR 53565

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com